Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 14/20 | 0.42 |
| ▸ | MMP1 | P03956 | 9/20 | 0.42 |
| ▸ | MMP3 | P08254 | 9/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 4/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2392222 | 1.00 | CSNK1E (0.55) | CSNK1EMMP2MMP1MMP3HTR2A | |
| SCHEMBL8387575 | 1.00 | CSNK1E (0.55) | CSNK1EMMP2MMP1MMP3HTR2A | |
| SCHEMBL8386222 | 1.00 | CSNK1E (0.55) | CSNK1EMMP2MMP1MMP3HTR2A | |
| SCHEMBL8382904 | 1.00 | CSNK1E (0.55) | CSNK1EMMP2MMP1MMP3HTR2A | |
| SCHEMBL25283495 | 1.00 | CSNK1E (0.55) | CSNK1EMMP2MMP1MMP3HTR2A | |
| SCHEMBL8386102 | 1.00 | CSNK1E (0.55) | CSNK1EMMP2MMP1MMP3HTR2A | |
| SCHEMBL25287896 | 1.00 | CSNK1E (0.55) | CSNK1EMMP2MMP1MMP3HTR2A | |
| SCHEMBL8385145 | 1.00 | CSNK1E (0.55) | CSNK1EMMP2MMP1MMP3HTR2A | |
| SCHEMBL8382112 | 1.00 | CSNK1E (0.55) | CSNK1EMMP2MMP1MMP3HTR2A | |
| SCHEMBL8381675 | 1.00 | CSNK1E (0.55) | CSNK1EMMP2MMP1MMP3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3503927-B1 | TOPICAL FORMULATIONS BASED ON IONIC SPECIES FOR SKIN TREATMENT | UNIV CALIFORNIA (US) | 2025-02-19 | — | — | EP | claimed |
| EP-4146765-B1 | A METHOD AND REAGENTS FOR ENHANCING THE CHEMILUMINESCENT SIGNAL | EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG (DE) | 2023-07-05 | — | — | EP | claimed |
| US-20220089455-A1 | METHOD FOR PRODUCING NANOPARTICLE HAVING METAL PARTICLE WHICH CONTAINS IRON OXIDE TO WHICH ONE OR MORE HYDROPHILIC LIGANDS ARE COORDINATION BONDED | ASTELLAS PHARMA INC. (JP) | 2022-03-24 | — | — | US | claimed |
| EP-3904294-A1 | METHOD FOR PRODUCING NANOPARTICLES INCLUDING METAL PARTICLES CONTAINING IRON OXIDE HAVING AT LEAST ONE HYDROPHILIC LIGAND COORDINATED THERETO | Astellas Pharma Inc. (JP) | 2021-11-03 | — | — | EP | claimed |
| CN-113226990-A | Method for producing nanoparticles comprising iron oxide-containing metal particles to which one or more hydrophilic ligands are coordinately bound | 安斯泰来制药株式会社 | 2021-08-06 | — | — | CN | claimed |
| US-20210162050-A1 | TOPICAL FORMULATIONS BASED ON IONIC SPECIES FOR SKIN TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-06-03 | — | — | US | claimed |
| US-10912834-B2 | Topical formulations based on ionic species for skin treatment | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-02-09 | — | — | US | claimed |
| WO-2020138404-A1 | METHOD FOR PRODUCING NANOPARTICLES INCLUDING METAL PARTICLES CONTAINING IRON OXIDE HAVING AT LEAST ONE HYDROPHILIC LIGAND COORDINATED THERETO | アステラス製薬株式会社 | 2020-07-02 | — | — | WO | claimed |
| EP-3240918-B1 | MITIGATION OF CORROSION IN GEOTHERMAL SYSTEMS | ECOLAB USA INC (US) | 2020-04-15 | — | — | EP | claimed |
| EP-3503927-A1 | TOPICAL FORMULATIONS BASED ON IONIC SPECIES FOR SKIN TREATMENT | The Regents of the University of California (US) | 2019-07-03 | — | — | EP | claimed |
| US-10252971-B2 | Method for producing halogenated acrylic acid derivative | AGC Inc. (JP) | 2019-04-09 | — | — | US | claimed |
| WO-2018044920-A1 | TOPICAL FORMULATIONS BASED ON IONIC SPECIES FOR SKIN TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-08 | — | — | WO | claimed |
| US-9428521-B2 | Process for the production of a carbodiimide | KAWAGUCHI CHEMICAL INDUSTRY CO., LTD. (JP) | 2016-08-30 | — | — | US | claimed |
| EP-2583971-B1 | METHOD FOR PRODUCING CARBODIIMIDE | KAWAGUCHI CHEMICAL INDUSTRY CO LTD (JP) | 2015-03-04 | — | — | EP | claimed |
| EP-2583971-A1 | METHOD FOR PRODUCING CARBODIIMIDE | Kawaguchi Chemical Industry Co. Ltd. (JP) | 2013-04-24 | — | — | EP | claimed |
| US-20130085274-A1 | PROCESS FOR THE PRODUCTION OF A CARBODIIMIDE | TEIJIN LIMITED (JP) | 2013-04-04 | — | — | US | claimed |
| EP-0707489-A4 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | SCOTGEN BIOPHARMACEUTICALS INC (US) | 1998-07-29 | — | — | EP | claimed |
| EP-0707489-A1 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | Scotgen Biopharmaceuticals, Inc. (US) | 1996-04-24 | — | — | EP | claimed |
| EP-0385504-B1 | Heat-latent curing catalyst and resin compositions containing the same | NIPPON PAINT CO LTD (JP) | 1995-10-04 | — | — | EP | claimed |
| WO-1994025053-A1 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | SCOTGEN BIOPHARMACEUTICALS, INC. (US) | 1994-11-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085274-A1 | PROCESS FOR THE PRODUCTION OF A CARBODIIMIDE | CTH, TST, CBS | CSNK1E 731/4885MMP2 2853/4885MMP1 3471/4885 |
| US-20210162050-A1 | TOPICAL FORMULATIONS BASED ON IONIC SPECIES FOR SKIN TREATMENT | CUTA, KRT18, SLC38A7 | CSNK1E 419/4885MMP2 201/4885MMP1 35/4885 |
| US-20220089455-A1 | METHOD FOR PRODUCING NANOPARTICLE HAVING METAL PARTICLE WHICH CONTAINS IRON OXIDE TO WHICH ONE OR MORE HYDROPHILIC LIGANDS ARE COORDINATION BONDED | FTH1, HAMP, TFRC | CSNK1E 4876/4885MMP2 4364/4885MMP1 4406/4885 |
| US-10252971-B2 | Method for producing halogenated acrylic acid derivative | C3AR1, HRH2, C5AR1 | CSNK1E 1219/4885MMP2 2006/4885MMP1 3001/4885 |
| US-10912834-B2 | Topical formulations based on ionic species for skin treatment | CUTA, KRT18, SLC38A7 | CSNK1E 419/4885MMP2 201/4885MMP1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.